Huntington's disease: underlying molecular mechanisms and emerging concepts
about
A dynamic interface between ubiquitylation and cAMP signalingRole of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesLarge-scale microfluidics providing high-resolution and high-throughput screening of Caenorhabditis elegans poly-glutamine aggregation model.Polyglutamine toxicity in yeast induces metabolic alterations and mitochondrial defectsRoles of tau protein in health and disease.Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.Biophysical underpinnings of the repeat length dependence of polyglutamine amyloid formationLaquinimod treatment in the R6/2 mouse model.Coexpression within Integrated Mitochondrial Pathways Reveals Different Networks in Normal and Chemically Treated Transcriptomes.Assemblages: functional units formed by cellular phase separationSkeletal muscle pathology in Huntington's diseaseProtein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition.A common gene expression signature in Huntington's disease patient brain regions.The biology of proteostasis in aging and disease.Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders.Prevalent polymorphism in thyroid hormone-activating enzyme leaves a genetic fingerprint that underlies associated clinical syndromesReduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease.Folding Landscape of Mutant Huntingtin Exon1: Diffusible Multimers, Oligomers and Fibrils, and No Detectable Monomer.The Spectrum of Psychiatric Pathology in a Patient with Genetically Verified Huntington's Disease.Impaired GAPDH-induced mitophagy contributes to the pathology of Huntington's disease.Beyond the redox imbalance: Oxidative stress contributes to an impaired GLUT3 modulation in Huntington's diseaseEffects of Pin1 Loss in Hdh(Q111) Knock-in Mice.Abnormal Weight and Body Mass Index in Children with Juvenile Huntington's Disease.αB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's diseaseRepeat-associated non-ATG (RAN) translation in neurological disease.Glycation potentiates neurodegeneration in models of Huntington's disease.miRNAs: Key Players in Neurodegenerative Disorders and EpilepsyContribution of Neuroepigenetics to Huntington's Disease.Emerging Synaptic Molecules as Candidates in the Etiology of Neurological Disorders.Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's diseaseTargeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease.Anti-amyloid compounds protect from silica nanoparticle-induced neurotoxicity in the nematode C. elegans.AMPK-mediated regulation of neuronal metabolism and function in brain diseases.Exosomes and Homeostatic Synaptic Plasticity Are Linked to Each other and to Huntington's, Parkinson's, and Other Neurodegenerative Diseases by Database-Enabled Analyses of Comprehensively Curated Datasets.Genetic Approaches to Understanding Psychiatric Disease.Huntington's disease: Molecular basis of pathology and status of current therapeutic approachesModulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.Group I Metabotropic Glutamate Receptor Interacting Proteins: Fine-Tuning Receptor Functions in Health and Disease.RNA toxicity induced by expanded CAG repeats in Huntington's disease.
P2860
Q26782981-123FBD87-B02E-4126-9150-3D7DFAC24702Q28072353-CD33408D-28A7-41FC-B447-5FD3D853AE10Q28554683-F9621E88-7941-45BB-90EA-2E0876DF1E6DQ30663550-D929D8F9-FCAE-45D6-B1B2-09D4B46D18DCQ33559303-8600F72D-E387-462D-B6C4-7864B3432E21Q33624262-F632C9F6-2CA0-412B-B66C-7C67474E031EQ33675599-85FC7596-6D4C-4CB9-8C61-91B42EC9DB54Q33890346-D1BF9FF4-73C3-4FE2-8378-21FB1941B6A2Q33892701-F52E4DE1-5A87-4453-B780-B4C9BBCC734CQ34117231-DC95F41D-27D1-42F4-B5B0-2AE02781C5DAQ34292092-F26DFE08-9140-4B89-B088-A1683E281A31Q34413909-633E72A8-60E1-44EC-B720-B4ECA81092D9Q34446889-1710463F-4179-4DCB-93B7-EA796A6BC72BQ34467650-2E3A878A-C365-4D66-8E80-F0AD8C81EFA0Q34543709-60F85F9A-BDBD-4882-B800-7FA8A6DAD8C7Q35096897-6C6CFD4C-9D73-4A8E-BB32-D30D741AF227Q35874721-71B23D4E-013C-4AFC-8851-6BBE62E66186Q36043574-03BC6F6D-3466-4C3D-B09B-D360E5FAA5E9Q36106163-EDF3E2DD-340A-4584-AB90-C83E863546B1Q36159463-022489C6-B2F2-4092-97A7-4F506235E488Q36824396-8F0C63E0-5E96-4CDF-AF6B-0CE29B695CB5Q36854994-7D8BE232-D9CD-4A8B-8EB1-482F447AD06EQ36950717-7599DB92-0CD4-4254-A44B-6B2798DE6C21Q37178561-F95DA96E-8AAF-4D3D-AA86-88F0091B84A4Q37195032-0E0A9685-3C52-42CE-BC23-C1565B923F3EQ37421997-83DE42D2-79E7-46F2-87AD-B77754FAB865Q37535111-C0E8E380-48BF-4F0A-9FD7-01844FED98B9Q37611722-86347F3C-C8F2-48FA-A878-09099F83165EQ37694175-1AD8F40E-E63A-4434-8F0F-C642B4EFF970Q37730673-0CED6A60-8EBF-42DD-B52D-D905EF2B6640Q38290349-47CA1600-54F4-4008-BC78-7950138766B1Q38343049-D46EEE0E-966E-47C4-82B8-557240FB37D5Q38456671-EC927D13-D739-4B94-8FBD-DE81D9E281E9Q38539535-F20BA27E-1180-4DE6-BCCC-7D2123966A93Q38726920-FF178E8B-CAE7-42ED-8266-C8B132E9E30CQ38728415-AB400BE4-CF1E-4479-B4E0-2B87ADE48A9DQ38815118-F41D6D84-9D17-41C5-B43F-3F829A3F3226Q38818474-F405EAF3-79E2-482F-94EE-31594D0E9607Q38863889-D5BFB289-999D-42B9-9633-6BEDFF77757DQ38928719-266A5C86-C852-419A-BA82-831E1F8649C4
P2860
Huntington's disease: underlying molecular mechanisms and emerging concepts
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Huntington's disease: underlying molecular mechanisms and emerging concepts
@ast
Huntington's disease: underlying molecular mechanisms and emerging concepts
@en
Huntington's disease: underlying molecular mechanisms and emerging concepts
@nl
type
label
Huntington's disease: underlying molecular mechanisms and emerging concepts
@ast
Huntington's disease: underlying molecular mechanisms and emerging concepts
@en
Huntington's disease: underlying molecular mechanisms and emerging concepts
@nl
prefLabel
Huntington's disease: underlying molecular mechanisms and emerging concepts
@ast
Huntington's disease: underlying molecular mechanisms and emerging concepts
@en
Huntington's disease: underlying molecular mechanisms and emerging concepts
@nl
P2860
P3181
P1476
Huntington's disease: underlying molecular mechanisms and emerging concepts
@en
P2093
John Labbadia
Richard I. Morimoto
P2860
P304
P3181
P356
10.1016/J.TIBS.2013.05.003
P407
P577
2013-08-01T00:00:00Z